Skip to main content
. Author manuscript; available in PMC: 2022 Sep 6.
Published in final edited form as: Biochem Pharmacol. 2017 Feb 15;131:68–77. doi: 10.1016/j.bcp.2017.02.006

Figure 1.

Figure 1

Rev-erb agonist SR9009 reduces the expression of cholesterol biosynthesis pathway genes and plasma cholesterol levels in C57Bl/6 mice. Male mice (n=6) were treated with SR9009 (100mg/kg, I.P. b.i.d.) for ten days. a) Body weight of mice at the end of the treatment. B) mRNA expression of cholesterol biosynthesis pathway genes in mouse liver. mRNA was normalized to Gapdh. c) Plasma levels of triglyceride, total cholesterol, LDL-cholesterol and HDL-cholesterol. Data are presented as the mean ± SE. Student’s t-test was used to calculate statistical significance. * indicates a p-value < 0.05.